摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylene}-1H-indene-3-acetic acid 4-(nitrooxy)butyl ester

中文名称
——
中文别名
——
英文名称
(Z)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylene}-1H-indene-3-acetic acid 4-(nitrooxy)butyl ester
英文别名
(Z)-4-(nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate;NO-sulindac;NCX-1102;NCX1102;Nitrosulindac;4-nitrooxybutyl 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetate
(Z)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylene}-1H-indene-3-acetic acid 4-(nitrooxy)butyl ester化学式
CAS
——
化学式
C24H24FNO6S
mdl
——
分子量
473.522
InChiKey
CMZSMYLJISCEDU-BKUYFWCQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    33
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    118
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    Sulindac硝酸4-羟基丁酯4-二甲氨基吡啶盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 二氯甲烷 为溶剂, 反应 4.0h, 以91%的产率得到(Z)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylene}-1H-indene-3-acetic acid 4-(nitrooxy)butyl ester
    参考文献:
    名称:
    Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment
    摘要:
    A series of analogues of the non-steroidal anti-inflammatory drug (NSAID) sulindac 1 were synthesised tethered to nitric oxide (NO) donating functional groups. Sulindac shows antiproliterative effects against immortal PC3 cell lines. It was previously demonstrated that the effect can be enhanced when tethered to NO releasing groups such as nitrate esters, furoxans and sydnonimines. To explore this approach further, a total of fifty-six sulindac-NO analogues were prepared and they were evaluated as NO-releasing cytotoxic agents against prostate cancer (PCa) cell lines. Compounds 1k and 1n exhibited significant cytotoxic with IC50 values of 6.1 +/- 4.1 and 12.1 +/- 3.2 mu M, respectively, coupled with observed nitric oxide release. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2013.12.014
点击查看最新优质反应信息

文献信息

  • Nitroderivatives as drugs for diseases having an inflammatory basis
    申请人:——
    公开号:US20040023933A1
    公开(公告)日:2004-02-05
    Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-X t -L-(W) p —NO 2 wherein A contains the radical of a drug, X t and W arc bivalent radicals, L, is a covalent bond or oxygen, sulphur, NR tc wherein R tc is H or a C 1 -C 5 linear or branched alkyl.
    用于治疗具有炎症基础的疾病的化合物或其盐,具有以下一般公式(I):A-X t -L-(W) p —NO 2 其中A含有药物的自由基,X t 和W是二价基团,L是共价键或氧、硫、NR tc ,其中R tc 是H或C 1 -C 5 的直链或支链烷基。
  • [EN] NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS<br/>[FR] NITRODERIVES UTILES EN TANT QUE MEDICAMENTS DESTINES A DES MALADIES D'ORIGINE INFLAMMATOIRE
    申请人:NICOX SA
    公开号:WO2002030866A1
    公开(公告)日:2002-04-18
    Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-X1-L-(W)p-NO2 wherein A contains the radical of a drug, X1 and W are bivalent radicals, L is a covalent bond or oxygen, sulphur, NR1c wherein R1c is H or a C1-C5 linear or branched alkyl.
    用于治疗具有炎症基础的疾病的化合物或其盐,其具有以下一般式(I):A-X1-L-(W)p-NO2,其中A包含药物的基团,X1和W是二价基团,L是共价键或氧,硫,NR1c,其中R1c是H或C1-C5线性或支链烷基。
  • NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS
    申请人:DEL SOLDATO Piero
    公开号:US20080194651A1
    公开(公告)日:2008-08-14
    Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, Having the following general formula (I): A-X 1 -L-(W) p —NO 2 wherein A contains the radical of a drug, X 1 and W are bivalent radicals, L is a covalent bond or oxygen, sulphur, NR 1e wherein R 1e is H or a C 1 -C 5 linear or branched alkyl.
    用于治疗具有炎症基础的疾病的化合物或其盐,其具有以下通式(I):A-X1-L-(W)p—NO2,其中A包含药物的基团,X1和W是双价基团,L是共价键或氧,硫,NR1,其中R1是H或C1-C5线性或支链烷基。
  • NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS
    申请人:DEL SOLDATO Piero
    公开号:US20090075952A1
    公开(公告)日:2009-03-19
    Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-X 1 -L-(W) p -NO 2 wherein A contains the radical of a drug, X 1 and W are bivalent radicals, L is a covalent bond or oxygen, sulphur, NR 1c wherein R 1c is H or a C 1 -C 5 linear or branched alkyl.
    用于治疗具有炎症基础的疾病的化合物或其盐,其具有以下一般式(I):A-X1-L-(W)p-NO2,其中A包含药物的基团,X1和W是二价基团,L是共价键或氧,硫,NR1c,其中R1c是H或C1-C5线性或支链烷基。
  • Pharmaceutical compounds
    申请人:Del Soldato Piero
    公开号:US20070197499A1
    公开(公告)日:2007-08-23
    Compounds or their salts of general formula (I): A-B—N(O) s wherein: s is an integer equal to 1 or 2; A=R-T 1 -, wherein R is the drug radical and T 1 =(CO) t or (X) t′ , wherein X═O, S, NR 1c , R 1c is H or a linear or branched alkyl or a free valence, t and t′ are integers and equal to zero or 1, with the proviso that t=1 when t′=0; t=0 when t′=1; B=-T B -X 2 —O—wherein T B =(CO) when t=0, T B =X when t′=0, X being as above defined; X 2 is equal to R 1B—X—R 2B radical wherein X is as above defined, R 1B and R 2B , equal to or different from each other, are linear or branched C 1 -C 6 alkylenes, or X 2 is a radical wherein two alkylene chains C 1 -C 4 are linked to nonadjacent positions of a central ring having 4 or 6 atoms, said ring being an unsaturated cycloaliphatic ring, or a saturated or aromatic heterocylic ring, containing one or two heteroatoms, equal or different, selected from O, S, N; wherein the unsaturated cycloaliphatic ring does not have aromatic character according to Huckel's rule.
    通式(I)的化合物或其盐:A-B-N(O)s其中:s是等于1或2的整数;A = R-T1-,其中R为药物基团,T1 =(CO)或(X)t',其中X = O,S,NR1c,R1c是H或线性或支链烷基或自由价,t和t'是整数,等于零或1,但前提是当t' = 0时,t = 1;当t' = 1时,t = 0;B = -TB-X2-O-,其中TB =(CO)当t = 0时,TB = X当t' = 0时,X如上定义;X2等于R1B-X-R2B基团,其中X如上定义,R1B和R2B相等或不同,是线性或支链C1-C6烷基,或X2是基团,其中两个C1-C4烷基链连接到具有4或6个原子的中心环的非相邻位置,该环是不饱和的环状脂肪族环,或饱和的或芳香的杂环,包含一个或两个异原子,相同或不同,从O,S,N中选择;其中不饱和的环状脂肪族环不具有根据Huckel法则的芳香性质。
查看更多

同类化合物

马来酸二甲茚定 螺[茚-1,4’-哌啶]盐酸盐 螺[茚-1,4-哌啶] 螺[1H-茚-1,4-哌啶]-3-羧酸盐酸盐 螺[1H-茚-1,4-哌啶]-1,3-二羧酸,1,1-二甲基乙酯 螺[1,3-二氧戊环-2,1'-茚] 茚洛秦 茚旦醇 茚并[2,1-a]茚 茚屈林 茚-2,3-二羧酸 苯酚,2-(1H-茚-3-基)- 苯茚达明酒石酸盐 苯茚胺 苯基亚甲基双(三环己基磷)二氯化钌 膦,1H-茚-1-基二苯基- 硬树脂 硫化舒林酸 硫化舒林酸 盐酸茚诺洛尔 盐酸茚洛秦 盐酸苯二胺 甲茚 甲基3-氨基-1H-茚-2-羧酸酯 甲基3-氨基-1-氰基-1-苯基-1H-茚-2-羧酸酯 甲基1-氧代-2-苯基-1H-茚-3-基碳酸酯 氨甲酸,[(1S)-1-甲基-2-(硝基氧代)乙基]-,1,1-二甲基乙基酯(9CI) 异苯茚达明 尿苷,2'-脱氧-5-(2-羟基乙基)-,3',5'-二(4-甲基苯酸酯)(9CI) 外消旋-N-去甲基二甲茚定 四氢荧蒽 四-1H-茚-1-ylstannane 吡喃达明盐酸盐 吡喃达明 叔-丁基6-甲基螺[茚并-1,4-哌啶]-1-甲酸基酯 叔-丁基6-氯螺[茚并-1,4-哌啶]-1-甲酸基酯 亚乙基二(4,5,6,7-四氢-1-茚基)二甲基锆(IV) 二茚并[1,2-b:2,1-e]吡啶-10,12-二酮,5,11-二氢-5-甲基- 二甲茚定 二甲基[二(2-甲基-1H-茚-1-基)]硅烷 二甲基-(2-吗啉-4-基-茚-1-亚基甲基)-胺 二环己基[2-(2,4,6-三甲基苯基)-1H-茚-3-基]膦 二-1H-茚-1-基-二甲基硅烷 三(异丙氧基)膦(3-苯基-1H-茚-1-基)[1,3-双(2,4,6-三甲基苯基)-4,5-二氢咪唑-2-基]钌(II)二氯化物 三乙基-茚-1-基-硅烷 rac-乙烯双(1-茚基)二氯化锆 [4-(4-叔丁基苯基)-2-异丙基-1H-茚-1-基][4-(4-叔丁基苯基)-2-甲基-1H-茚-1-基]二甲基硅烷 [(1Z)-5-氟-2-甲基-1-(3-噻吩基亚甲基)-1H-茚-3-基]乙酸 N,N-二甲基-3-[(1S)-1-(2-吡啶基)乙基]-1H-茚满-2-乙胺马来酸酯